Transthyretin Amyloidosis (ATTR) | Pfizer Medical Information - Saudi Arabia (Kingdom of Saudi Arabia, المملكة العربية السعودية)

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.

Back to Diseases Areas

Poster

Marianna Bruno, Radhika Nair, Casey Reed, Alexander Schepart, Richard Sheer, Edward W. Casey, Jeff D. Simmons March 29, 2022 AMCP 2022 Transthyretin Amyloidosis (ATTR)

Applying a Machine Learning Model in a Claims Database to Characterize Patients With Heart Failure at High Risk for Wild-Type Transthyretin Amyloid Cardiomyopathy

View Presentation

Poster

Bhambri R, Colavecchia C, Bruno M, Chen Y, Alvir J, Roy A, Kemner J, Crowley A, Benjumea D, Gilstrap L April 2, 2022 ACC 2022 Transthyretin Amyloidosis (ATTR)

Characteristics of patients with wild-type transthyretin cardiac amyloidosis prescribed tafamidis - a real-world descriptive analysis using electronic health records

View Presentation

Poster

Sperry BW, Hanna MA, Maurer MS, Nativi-Nicolau J, Floden L, Stewart M, Wyrwich K, Barsdorf A, Kapadia H, Spertus JA April 2, 2022 ACC 2022 Transthyretin Amyloidosis (ATTR)

Health status in patients with ATTR cardiac amyloidosis receiving tafamidis: responder analysis from ATTR-ACT

View Presentation

Poster

Elliott P, Gundapaneni B, Sultan MB, Ines M, Garcia-Pavia P May 21, 2022 HFA 2022 Transthyretin Amyloidosis (ATTR)

Improved Survival With ~5 Years of Continuous Tafamidis Treatment Among Patients With NYHA Class III Transthyretin Amyloid Cardiomyopathy

View Presentation

Oral Presentation

Garcia-Pavia P, Piriou N, Barriales-Villa R, Cappelli F, Lairez O, Munteanu C, Keohane D, Mallaina P May 21, 2022 HFA 2022 Transthyretin Amyloidosis (ATTR)

Prevalence and characteristics of transthyretin amyloid cardiomyopathy in patients with left ventricular hypertrophy in the TTRACK study: An interim analysis

View Presentation

Poster

Witteles R, Sultan MB, Gundapaneni B, Garcia-Pavia P August 26, 2022 ESC 2022 Transthyretin Amyloidosis (ATTR)

Atrial Fibrillation as a Prognostic Factor for All-Cause Mortality in Patients With Transthyretin Amyloid Cardiomyopathy

View Presentation

Poster

Moody AT, Tess DA, Li Z, Bulawa C, Fleming J, Maurer TS August 26, 2022 ESC 2022 Transthyretin Amyloidosis (ATTR)

Relationship of Tafamidis Binding-Site Occupancy, Transthyretin Stabilization, and Disease Modification in Tafamidis-Treated Patients With Transthyretin Amyloid Cardiomyopathy

View Presentation

Poster

Gonzalez-Moreno J, Dispenzieri A, Grogan M, Coelho T, Tournev I, Waddington-Cruz M, Wixner J, Diemberger I, Garcia Pavia P, Chapman D, Glass O, Amass L September 5, 2022 ISA 2022 Transthyretin Amyloidosis (ATTR)